Shots:

• The P-III HLX03-Ps03 study involves comparing the efficacy- safety and immunogenicity assessing of HLX03 (80mg- qd) with reference adalimumab in 262 Chinese patients in the ratio of (1:1) with moderate to severe plaque psoriasis
• Result: On 1EPs % improvement of PASIwk16 (83.48% vs 82.02%)- least square mean difference (1.46%)- no significant differences between the treatment groups in 2EPs that include PASI 75- PGA reaching clearance and change in DLQI
• HLX03 is an adalimumab biosimilar to be used for the treatment of autoimmune diseases including psoriasis- RA & AS

  Ref: Henlius | Image: BioSpectrum Asia